|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |
Abstract |
|---|
|
|
|---|
Fourteen-member-ring macrolides are antibiotics with a variety
of anti-inflammatory activities, and have repeatedly been reported to reduce mucus hypersecretion in conditions such as
cystic fibrosis and bronchiectasis. Their structure is characterized by a macrocyclic lactone ring. Because human neutrophil
elastase (HNE) plays a crucial role in the vicious circle leading to
mucus hypersecretion, and lactones are known to be elastase inhibitors, we hypothesized that macrolides might directly inhibit
elastase. To investigate this hypothesis we designed a series of
spectrophotometric experiments using a chromogenic substrate
with two macrolides, erythromycin (Er) and flurythromycin
(FE). We determined the 1st order rate constant (kobs) by inhibition and competitive substrate assays, the latter allowing us
to calculate the substrate binding constant or inhibition constant and the acylation rate constant (ka). A proflavine displacement assay was used to determine the deacylation rate
constant (kd). Both Er and FE are good HNE inhibitors, showing a high ka and a low kd. Because the number of turnovers per inactivation of Er was
20-fold higher than that of FE, we supposed that the lower reactivation of HNE-FE was due to the
formation of a more stable inactivated enzyme. This hypothesis was confirmed by the hydrazine reactivation of the acyl enzyme. For Er we identified a kd only, whereas for FE, in addition
to the kd, an alkylation constant (k2) was calculated, correlated
to a fully inactivated enzyme. From our kinetics data, we therefore conclude that Er acts as an alternate substrate HNE inhibitor, whereas FE acts as an inactivator.
| |
Introduction |
|---|
|
|
|---|
Macrolides, including erythromycin (Er), are antibiotics with bactericidal effects. There is, however, an increasing body of evidence demonstrating that macrolides may have activities not related to their antibiotic properties. Er A and its derivatives (especially 14-member-ring macrolides, such as roxithromycin and clarithromycin) can significantly inhibit the neutrophil oxidative burst in vitro (1). The same compounds have also been shown to reduce spontaneous interleukin (IL)-6 (2) and IL-8 expression in human bronchial epithelial cells (3) and the Hemophilus influenzae endotoxin-induced release of IL-6 and IL-8 by these cells (4). In addition, macrolides are able to inhibit lipopolysaccharide (LPS)-induced goblet-cell hypersecretion in an animal model (4). Suppression of LPS-induced intrapulmonary neutrophil influx (5), and activities on airway epithelial cell and gland electrolyte secretion (6, 7), may both contribute to this inhibition. Taken together, such a variety of anti- inflammatory effects account for the in vivo efficacy of macrolides in conditions such as diffuse panbronchiolitis, cystic fibrosis, and bronchiectasis characterized by a "vicious circle" leading to mucus hypersecretion (8).
Human neutrophil elastase (HNE) is an important component in the establishment of the vicious circle in the previously mentioned conditions (13). It has been reported that Er treatment results in a reduction of neutrophil-derived elastolytic activity in the airways of subjects with chronic airway disease (8) and diffuse panbronchiolitis (14). Such a feature was, however, attributed to a direct effect of Er on neutrophil function. The structure of Er is characterized by a macrocyclic lactone ring (Figure 1). Interestingly, several types of lactones (ynenol, protio, and halo enol lactones) are heterocyclic compounds capable of inhibiting HNE (15). Such structural homology raises the question of whether Er might exert a direct inhibitory effect on HNE.
|
We therefore designed a series of experiments aimed at evaluating whether or not Er is an HNE inhibitor and, if so, by what mechanism this activity is exerted. In this study, experiments were also performed with the semisynthetic macrolide flurythromycin (FE) base, a 14-membered 8-fluoro-macrolide (Figure 1) obtained by mutasynthesis using a mutant strain of the Er producing microorganism (16), to understand whether 14-membered fluorinated macrolides retain the same activity and mechanism of action as Er.
| |
Materials and Methods |
|---|
|
|
|---|
Chemicals and Equipment
In this study we used phosphate buffer 0.1 M NaH2PO4- Na2HPO4, pH 8.0, with 0.05% wt/wt Triton X-100 and 0.5 M NaCl. HNE was purchased from ART (Athens, GA) and active-site titrated in all experiments by MeO-Suc-Ala-Ala-Pro-Val-CH2-Cl, as described elsewhere (17). HNE was dissolved in 50 mM CH3COONa, pH 5.5, supplied with 150 mM NaCl and diluted in the previously described phosphate buffer. Chromogenic substrate MeO-Suc-Ala-Ala-Pro-Val-pNa (Sigma, St. Louis, MO) was dissolved and diluted in Me2SO. Er was purchased from Sigma, and FE base (Pierrel SpA, batch #60296) was a kind gift from Pharmacia & Upjohn (Milan, Italy); both were dissolved and diluted in Me2SO. Proflavine (Sigma) was dissolved and diluted in phosphate buffer as described earlier. Hydrazine (Sigma) was diluted in distilled water. Assays were performed at 26 ± 1°C using a Beckman DU 650 L spectrophotometer. All assay cuvettes contained enough Me2SO to obtain a final cosolvent concentration of 10%. Changes in absorbance at 410 and 466 nm were recorded in cuvettes with 1 cm optical course and through a total volume of 1 ml.
Definition of Michaelis Constant
A constant amount of HNE (2.6 × 10
8 M) and serial dilutions of
substrate (ranging from 2 × 10
3 M to 9.8 × 10
7 M) were combined into the cuvettes. Reactions, recorded in triplicate over a
time interval of 3 min, were started with addition of substrate dilutions. Estimations of maximal velocity (Vmax) and Michaelis constant (Km) were made according to Eisenthal and Cornish-Bowden (18).
Km (± standard deviation [SD]), 4.2685 ± 0.1236 × 10
5 M.
catalytic rate constant (kcat) (± SD), 4.131 ± 0.5986 s
1.
kcat/Km, 96,778.7 M
1 s
1.
Vmax (± SD), 0.1325 ± 0.0159 s
1.
Enzyme Inhibition Assay Method A: No Deacylation Delay (19)
The concentrations used for enzyme inactivation were: HNE, 1 × 10
6 M; inhibitor(s) (Er or FE), 5 × 10
5 M; and substrate 3 × 10
4 M. The inhibitor(s) solution was added to a buffered enzyme solution and, at various intervals over the course of 2 h, aliquots were withdrawn and diluted 50 to 100-fold into a cuvette
containing a buffered solution of substrate. Substrate hydrolysis
was read immediately at 410 nm and was used to determine the
remaining enzyme activity versus a control solution without inhibitor. A semilogarithmic plot of enzyme activity (ln E/E0) versus time showed the inhibition rate kobs that was obtained from
the slope of the initial linear portion of the curves.
Enzyme Inhibition Assay Method B: 10-Min Deacylation Delay (19)
This method is identical to method A, with the exception that aliquots were diluted into cuvettes containing buffer. After 10 min, during which unstable acyl enzyme intermediates were allowed to decompose, substrate was added and the rates were measured at 410 nm. At the end of the 2 h, the enzyme incubation solutions showing greater than 10% inhibition with respect to the control were treated with 50 mM hydrazine and enzyme activity was monitored for additional 30 min.
Competitive Substrate Assay: Determination of the Substrate Binding Constant (Ks) or Inhibition Constant (Ki), and Acylation Rate Constant (ka) (19, 20)
Concentrations used for the assays were: HNE, 5 × 10
9 M; substrate, 3 × 10
5 M; Er and FE ranging from 1 × 10
7 M to 5 × 10
5 M. Reactions started with the addition of HNE and were recorded in triplicate over 30 min. During this assay it was assumed
that concentrations of both substrate and inhibitor remained constant, due to the large excess of those with respect to the enzyme.
When inhibitors were incubated with HNE and substrate there
was competition between inhibitor and substrate in occupying
the HNE active site. Kinetic analysis, according to Main (21), was
derived from competitive assay between substrate and a time-
dependent, irreversible inhibitor with corrections, according to
Baek and colleagues (20), due to inhibitors that are alternate substrates. The limiting slope of the progress curves, due to deacylation of the inhibitor acyl enzyme, was estimated and subtraction
of this rate from the curves allowed accurate determination of
the true exponential approach to steady-state (kobs). The absorbance changes against time were corrected for the limiting slope
and the semilogarithmic plots. These results gave a straight line
with a slope of kobs (first-order rate constant).
Main (21) described the progress curves for substrate consumption in time-dependent inhibition with equations (1) and (2):
|
(1) |
|
(2) |
where S0 and I0 are the initial concentrations of substrate and inhibitor, respectively; and V0 and V are the velocity of substrate hydrolysis at initial time and time t, respectively.
Rearrangement of the definition of kobs gives equation (2). A
plot of I0/kobs (second-order rate constant) versus the initial inhibitor concentration I0 gave a straight line with the slope 1/ka
and x intercept of
Ks(1 + S0/Km) or
Ki(1 + S0/Km).
|
In our assays condition S0 was 30 µM and Km was 42,685 µM.
Determination of Deacylation Rate Constant (kd) for Macrolide Inhibition: Proflavine Displacement Assay (20)
Maximal difference in absorbance between free proflavine and enzyme-proflavine complex is recorded at 466 nm, so the measurement of absorbance increase at this wavelength can be used to monitor acyl-enzyme decay. When an inhibitor (3.3 µM) was added to a solution of HNE (3.3 µM) and proflavine (0.33 µM) and the time-dependent absorbance change was monitored at 466 nm for 15 min (in triplicate), an initial fast disappearance of the enzyme-dye spectrum was seen. The decrease in absorbance was due to enzyme acylation and thus dissociation of proflavine, whereas the slow increase was due to deacylation of acyl-enzyme and rebinding of proflavine to free enzyme. The rate constant of deacylation of both mixtures and of separated enantiomers (see RESULTS) was calculated directly from the second phase of the progress curve of the enzyme-dye spectrum (method A, according to Baek and associates [20]).
Ultimate Activity Assays (19, 22)
A series of incubation solutions containing inhibitor(s) to enzyme molar ratios ranging from 0 to 50 were prepared mixing HNE, 1 × 10
6 M, and a solution of inhibitor ranging from 0 to
5 × 10
5 M. The enzyme activity remaining 16 h after the addition of the inhibitor was determined by diluting 1:20 an aliquot of
the incubation mixture into the buffer. After 10 min, the substrate
(3 × 10
4 M) was added and substrate hydrolysis was monitored
at 410 nm. A plot of the final enzyme activities versus the initial
inhibitor-to-enzyme concentration ratios gave a straight line with
an x intercept representing the number of turnovers per inactivation.
Hydrazine Reactivation Assays (19, 22)
Inactivated enzyme solutions were treated with the nucleophile
hydrazine (5 × 10
2 M), and enzyme activity was monitored over
40 h. HNE (1 × 10
6 M) was totally inhibited with a 50-fold excess of inhibitor(s). After 60 min, the aqueous hydrazine solution
was added and enzyme activity versus a control solution (no inhibitor) was monitored over the course of a 40-h period. This was
accomplished by periodic 1:20 dilutions of aliquots of incubation
solutions into the buffer. After 10 min, the remaining enzyme activity was assayed with 3 × 10
4 M substrate. Reactivated enzyme activity was plotted versus time.
| |
Results |
|---|
|
|
|---|
Inhibition Assays
Er at 50 µM rapidly (30 min) inhibited 15% of HNE activity and the inactivation rate progressively decreased, until cessation. However, inhibition was temporary and full activity was regained within 1 h. Temporary inhibition of this nature is consistent with the formation of a moderately stable acyl enzyme intermediate from Er and HNE that causes a temporary suppression of HNE activity until the inhibitor is completely turned over (19). Recovery of enzyme activity was rapid (15 min) after addition of the deacylating nucleophile hydrazine (50 mM). Er acts as a potential alternate substrate inhibitor and so should interact with the enzyme in the manner of a normal substrate.
The kinetic model shown in equation (3) describes the transient inhibitory activity of an alternate substrate inhibitor (19, 20):
|
(3) |
where I is the inhibitor, E.I the Michaelis complex, E*I the acyl enzyme (hydrazine-susceptible), and I' the hydrolyzed inhibitor.
FE (50 µM) showed a significant inhibition of HNE that was time-dependent and began immediately upon mixing. The recovery of enzyme activity observed within 30 min after the addition of 50 mM hydrazine was < 10%. We supposed that the complete inhibition was the result of either direct alkylation of the acyl enzyme intermediate by the reactive inhibitor moiety, or the formation of an extremely stable acyl enzyme intermediate. FE acts as an inactivator, with a mechanism of inactivation described in equation (4) (19):
|
(4) |
|
where I is the inactivator, E.I the Michaelis complex, E*I
the acyl-enzyme, E
I the permanently inactivated enzyme (hydrazine-resistant), and E + I' the free enzyme.
Acyl enzyme formation proceeds as with a normal substrate in a manner that is consistent with a mechanismbased inhibition process which can be described by Ki, ka, but it is followed by an inactivation event (alkylation) k2 which competes with deacylation kd.
Acylation of HNE by Er and FE: Competitive Substrate Assay
The rate of substrate turnover, measured continuously during the course of the enzyme acylation by the inhibitor(s),
decreased at a first-order rate constant, kobs (Figure 2). Ks
or Ki characterizes the affinity of the inhibitor toward the
active site of HNE and is a measure of the stability of the
E.I complex (20). In both cases, Ks or Ki was about 10
6 M
(Figure 3A); no great differences were observed in ka and
kd (Figure 3B). The second-order rate constants for the two
inhibitors, derived from the competitive substrate assay
(Figures 2B and 2C) and confirmed by the inhibition assay
without deacylation delay (Figure 2A), were good. According to Reed and Katzenellenbogen for protio and/or halo
lactones (19), the observed specificity of the inhibitors (Table 1) was consistent with an acyl-enzyme structure similar
to that adopted by a peptide substrate (23, 24).
|
|
|
Deacylation of HNE by Er and FE: Proflavine Displacement Assay
Deacylation of both macrolides resulted in a biphasic curve (Figure 3B). This occurrence was probably due to the presence in Er and FE solutions of two enantiomers, of which one was in large excess over the other, as confirmed by capillary electrophoresis experiments (data not shown). Compared with ka, kd is very slow; this step is therefore truly the rate-determining step for Er but not for FE, where k2 is the most probable pathway (Table 2).
|
Efficiency of the Inactivation of HNE by Er and FE: Ultimate Activity Assay
The inactivation efficiency for inhibitors of HNE was determined by measurement of the partition ratios or the number of turnovers per inactivation (number of turnovers per inactivation = partition ratio + 1) (22) (Figure 4 and Table 3). At low inhibitor-to-enzyme concentration ratios, inhibitor turnover caused significant deviation from linearity and incomplete inhibition. FE acylates the enzyme and the acyl enzyme will partition between being inactivated and deacylated; Er, on the other hand, acylates the enzyme, which deacylates. The number of equivalent of inhibitor necessary to inactivate the enzyme completely was determined for a period to allow complete consumption of inhibitor(s) (19). HNE was inactivated more efficiently by FE than by Er.
|
|
Permanence of Inactivation of HNE by FE: Hydrazine Reactivation Assay
The nature of the covalent attachment between the inhibitors and HNE in the completely inactivated enzyme species was investigated by treatment with the nucleophile hydrazine for an extended period of time. The relatively labile acyl serine linkage of a stable acyl enzyme is generally cleaved rapidly by hydrazine, whereas covalent attachment via alkylation by the reactive moiety on the inhibitor(s) is stable (19). When HNE that had been completely inactivated by FE was treated with 50 mM hydrazine and monitored for enzyme activity, less than 10% of control activity was recovered over a period of 1 h (Figure 5 and Table 3). This shows that haloketone, tethered to the active-site serine, alkylates an active-site nucleophile to give an inactivated enzyme. By contrast, when HNE that had been completely inactivated by Er was treated with hydrazine and monitored over 40 h, a recovery of about 50% was observed within 5 h (> 80% at 30 h) (Figure 5, inset; and Table 3). The inactivated enzyme possesses a less-stable covalent attachment that is susceptible to cleavage by hydrazine.
|
| |
Discussion |
|---|
|
|
|---|
In this paper we provide evidence that Er and FE, two 14-member-ring macrolides, can inhibit HNE.
The presence of a macrocyclic lactone ring in such compounds prompted us to explore the possibility that the macrolides investigated act as HNE inhibitors in a fashion similar to that displayed by lactones. Such heterocyclic elastase inhibitors are capable of being attacked by the nucleophilic active serine hydroxyl of the proteinase to give a ring-opened acyl enzyme intermediate. On the basis of the structure of the acyl enzyme intermediate, they may be categorized into two groups (19). Protio enol lactones act simply as substrates, forming very stable acyl enzyme intermediates, and the enzymes remain inhibited for the lifetime of the acyl enzyme species. Protio enol lactones belong to the group of alternate substrate inhibitors (or simple acylating agents), which also comprises benzoxazinones, 3-alkoxy-4-chloroisocoumarins, isobenzofuranones, and saccharin derivatives (15). By contrast, halo enol lactones and ynenol lactones are irreversible inhibitors with a latent, reactive functional group that is unmasked upon reaction with the active-site residue of the enzyme. This results in an acyl enzyme intermediate consisting of an enzyme tethered to a reactive functional group at the active site (Ser-195), and a simultaneous unmasking of the reactive group, giving a covalently modified enzyme that is permanently inactivated (15, 19). Such lactones are categorized as inactivators (also called "suicide inhibitors," kcat inhibitors, or enzyme-activated inhibitors), and the category also includes cephalosporins, 3,4-dichloroisocoumarins, 3-alkoxy- 7-amino-4-chloroisocoumarins, and halomethyldihydrocoumarins (25).
Similar to lactones, macrolides studied in this work have
an -O-CO-group. The -CH3 group in
position (Figure 1)
allows us to consider them as S enantiomers (19). This stereochemistry makes Er and FE good HNE substrates (20) (Figure 1, inset). Er acts as an alternate substrate inhibitor, its action appearing to involve acyl transfer to Ser-195, with
generation of an acyl enzyme (26), according to the scheme
reported in Figure 6. By contrast, FE acts as an inactivator:
enzyme acylation results in the formation of a halo ketone
derivative which can alkylate an active site nucleophile
(probably His-57) to give an inactivated enzyme (26). An alternative scheme for the putative inactivation mechanism of
HNE by FE is summarized in Figure 7: (1) HNE Ser-195 attacks the "lactonic carbon" to generate an acyl enzyme; (2) HNE His-57 catalyzes a trans elimination of the carbohydrate moiety; and (3) a nucleophilic attack to the acrylic ester
structure, most likely catalyzed by HNE His-57, generates a
stable doubly covalent adduct. Due to stereochemical difference in Er, the previously cited trans elimination reaction
would not be possible.
|
|
Both Er and FE are good HNE inhibitors because they
have a high capacity of acylation (ka) and a low velocity of
deacylation (kd). Because the Ks (or Ki) ratio FE: Er
2, in
the case of FE, the E
I interaction in the Michaelis complex is poorer than that between Er and HNE. Because the
number of turnovers per inactivation of Er is
20-fold
higher than that of FE (Table 3), we hypothesized that the
inactivated enzyme (E
I) HNE-FE was more stable than HNE-Er. Results of the hydrazine reactivation of the acyl
enzyme (Figure 5) showed that the acyl enzyme (E*I) HNE-
FE was more stable than the acyl complex HNE-Er. For
Er we identified only a deacylation constant (kd), whereas
for FE, in addition to the kd we were able to calculate an
alkylation constant (k2) correlated to a fully inactivated enzyme. Rates of enzymatic deacylation were identical for all
the substrates. However, for FE the determining step was
correlated to k2 connected to a reaction with 20-fold higher
rate with respect to kd. Therefore, FE is able to inactivate HNE almost fully. However, plots of hydrazine reactivation (Figure 5, inset) show that the percentages of reactivated enzyme at 30 min were 28.5 and 7% for Er and FE,
respectively, both in comparison with control. We then hypothesized that, at most, 7% of enzyme was exclusively affected by acylation, whereas the remainder was affected by
both acylation and alkylation. The same plots at 40 h
showed that the percentages of reactivated enzyme were 83 and 0.11% for Er and FE, respectively (Figure 5).
We can therefore conclude from our kinetics data that Er acts as an alternate substrate HNE inhibitor, whereas FE acts as an HNE inactivator. However, only crystal structure data would allow us to advance a more detailed hypothesis to elucidate inhibition mechanisms and enantioselectivity of these macrolides.
It remains to be established whether or not the inhibitory effect of the two 14-member-ring macrolides shown in this paper may in part account for the effects displayed in vivo by macrolides in conditions characterized by an excess of neutrophil elastase within the airways. Animal models of acute and chronic lung injury due to HNE would help, at least in part, to address such an issue. On the basis of the Ks or Ki value obtained, we may suppose that both Er and FE have moderate inhibitory activity in vivo and, on the basis of the inhibition mechanism, that FE would be more effective than Er. However, if our kinetic findings are relevant in vivo, inhibition of HNE might be an additional explanation for the reported effect of macrolides of reducing mucus hypersecretion in chronic conditions characterized by an excess of HNE within the airways, such as cystic fibrosis and disseminated bronchiectasis (11, 12). In fact, it is well known that HNE plays a crucial role in such conditions, causing direct stimulation of mucus secretion from airway glands (27) and stimulation of IL-8 production from epithelial cells (28) which, being a potent neutrophil chemoattractant, perpetuates a further HNE release (29). Macrolides have been reported to be able to suppress these events in vitro (3). Thus, a putative in vivo inhibition of HNE by macrolides might block two important mechanisms of the vicious circle leading to mucus hypersecretion, thus providing a further explanation for the more-than- expected efficacy of macrolides in this context. In addition, it would be interesting to investigate in future studies second-generation macrolide antibiotics, such as azithromycin or clarithromycin, and, maybe more interestingly, novel organic compounds produced by genetic manipulation (30) under this point of view.
| |
Footnotes |
|---|
Address correspondence to: Dr. Maurizio Luisetti, Laboratorio di Biochimica e Genetica, Clinica di Malattie dell'Apparato Respiratorio, IRCCS Policlinico San Matteo, Via Taramelli 5,27100 Pavia, Italy. E-mail: m.luisetti{at}smatteo.pv.it
(Received in original form March 9, 2001).
Abbreviations: erythromycin, Er; flurythromycin, FE; human neutrophil elastase, HNE; interleukin, IL; alkylation constant, k2; acylation rate constant, ka; catalytic rate constant, kcat; deacylation rate constant, kd; inhibition constant, Ki; Michaelis constant, Km; 1st order rate constant, kobs; substrate binding constant, Ks; standard deviation, SD.Acknowledgments: The authors are deeply indebted to Chih-Min Kam for helpful suggestions during the preparation of the manuscript. This work was supported in part by the Italian Ministry of Health, CF project, law 548/93, with a grant given to IRCCS Policlinico San Matteo. An unrestricted educational grant from Pharmacia & Upjohn is gratefully acknowledged.
| |
References |
|---|
|
|
|---|
1. Abdelghaffar, H., D. Vazifeh, and M.-T. Labro. 1997. Erythromycin A-derived macrolides modify the functional activities of human neutrophils by altering the phospholipase D-phosphatidate phosphohydrolase transduction pathway. J. Immunol. 159: 3995-4005 [Abstract].
2. Takizawa, H., M. Desaki, T. Ohtoshi, T. Kikutani, H. Okazaki, M. Sato, N. Akiyama, S. Shoji, K. Hiramatsu, and K. Ito. 1995. Erythromycin suppresses interleukin 6 expression by human bronchial epithelial cells: a potential mechanism of its anti-inflammatory action. Biochem. Biophys. Res. Commun. 210: 781-786 [Medline].
3.
Takizawa, H.,
M. Desaki,
T. Ohtoshi,
S. Kawasaki,
T. Kohyama,
M. Sato,
M. Tanaka,
K. Kobayashi,
J. Nakajima, and
K. Ito.
1995.
Erythromycin
modulates IL-8 expression in normal and inflamed human bronchial epithelial cells.
Am. J. Respir. Crit. Care Med.
156:
266-271
4. Khair, O. A., J. L. Devalia, M. M. Abdelaziz, R. J. Sapsford, and R. J. Davies. 1995. Effect of erythromycin on Haemophilus influenzae endotoxin-induced release of IL-6, IL-8 and sICAM-1 by cultured human bronchial epithelial cells. Eur. Respir. J. 8: 1451-1457 [Abstract].
5. Tamaoki, J., K. Takeyama, I. Yamawaki, M. Kondo, and K. Konno. 1997. Lipopolysaccharide-induced goblet cell hypersecretion in the guinea pig trachea: inhibition by macrolides. Am. J. Physiol. 272(Lung Cell. Mol. Physiol. 16):L15-L19.
6.
Kondo, M.,
S. Kanoh,
J. Tamaoki,
H. Shrirakawa,
S. Miyazaki, and
A. Nagai.
1998.
Erythromycin inhibits ATP-induced intracellular calcium responses in
bovine tracheal epithelial cells.
Am. J. Respir. Cell Mol. Biol.
19:
799-804
7. Irokawa, T., T. Sasaki, S. Shimura, K. Sasamori, T. Oshiro, M. Nara, T. Tamada, and K. Shirato. 1999. Cholinomimetic action of macrolide antibiotics on airway gland electrolyte secretion. Am. J. Physiol. 276(Lung Cell. Mol. Physiol. 20):L951-L957.
8.
Oishi, K.,
F. Sonoda,
S. Kobayashi,
A. Iwagaki,
T. Nagateke,
K. Matsushima, and
K. Matsumoto.
1994.
Role of interleukin-8 (IL-8) and an inhibitory effect of erythromycin on IL-8 release in the airways of patients with
chronic airway diseases.
Infect. Immun.
62:
4145-4152
9.
Kudoh, S.,
A. Azuma,
M. Yamamoto,
T. Izumi, and
M. Ando.
1998.
Improvement of survival in patients with diffuse panbronchiolitis treated
with low-dose erythromycin.
Am. J. Respir. Crit. Care Med.
157:
1829-1832
10. Kudoh, S.. 1998. Erythromycin treatment in diffuse panbronchiolitis. Curr. Opin. Pulm. Med. 4: 116-121 . [Medline]
11. Jaffé, A., J. Francis, M. Rosenthal, and A. Bush. 1998. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet 351: 420 [Medline].
12. Tsang, K. W. T., P.-I. Ho, K.-N. Chan, M. S. M. Ip, W.-K. Lam, C.-S. Ho, K. Y. Yuen, G. C. Ooi, R. Amitani, and E. Tanaka. 1999. A pilot study of low-dose erythromycin in bronchiectasis. Eur. Respir. J. 13: 361-364 [Abstract].
13. Döring, G.. 1994. The role of neutrophil elastase in chronic inflammation. Am. J. Respir. Crit. Care Med. 150: S114-S117 .
14. Ichikawa, Y., H. Ninomiya, H. Koga, M. Tanaka, M. Kinoshita, N. Tokunaga, T. Yano, and K. Oizumi. 1992. Erythromycin reduces neutrophils and neutrophil-derived elastolytic-like activity in the lower respiratory tract of bronchiolitis patients. Am. Rev. Respir. Dis. 146: 196-203 [Medline].
15. Powers, J. C., R. R. Plaskon, and C.-M. Kam. 1996. Low-molecular weight inhibitors of neutrophil elastase. In Alpha 1-Antitrypsin Deficiency. R. G. Crystal, editor. Marcel Dekker, Inc., New York. 341-370.
16. Pierrel, SpA. Flurythromycin Ethylsuccinate. Data on file. September 1993.
17. Baici, A., R. Pelloso, and D. Horler. 1990. The kinetic mechanism of inhibition of human leukocyte elastase by MR889, a new cyclic thiolic compound. Biochem. Pharmacol. 39: 919-924 [Medline].
18. Eisenthal, R., and A. Cornish-Bowden. 1974. The direct linear plot. A new graphical procedure for estimating enzyme kinetic parameters. Biochem. J. 139: 715-720 [Medline].
19.
Reed, P. E., and
J. A. Katzenellenbogen.
1991.
Proline-valine pseudo peptide enol lactones. Effective and selective inhibitors of chymotrypsin and
human leukocyte elastase.
J. Biol. Chem.
266:
13-21
20.
Baek, D.-J.,
P. E. Reed,
S. B. Daniels, and
J. A. Katzenellenbogen.
1990.
Alternate substrate inhibitors of an
-chymotrypsin : enantioselective interaction of aryl-substituted enol lactones.
Biochemistry
29:
4305-4311
[Medline].
21. Main, A. R. 1973. In Essays in Toxicology. Vol. 4. W. J. Hays, editor. Academic Press, New York. 59-105.
22.
Daniels, S. B.,
E. Cooney,
M. J. Sofia,
P. K. Chakravarty, and
J. A. Katzenellenbogen.
1983.
Haloenol lactones. Potent enzyme-activated irreversible inhibitors for alpha-chymotrypsin.
J. Biol. Chem.
258:
15046-15053
23. Ringe, D., J. M. Mottonen, M. H. Gelb, and R. H. Abels. 1986. X-ray diffraction analysis of the inactivation of chymotrypsin by 3-benzyl-6-chloro-2-pyrone. Biochemistry 25: 5633-5638 [Medline].
24. Harper, J. W., and J. C. Powers. 1985. Reaction of serine proteases with substituted 3-alkoxy-4-chloroisocoumarins and 3-alkoxy-7-amino-4-chloroisocoumarins: new reactive mechanism-based inhibitors. Biochemistry 24: 7200-7213 [Medline].
25. Vilain, A. C., V. Okochi, I. Vergely, M. Reboud-Ravaux, J. P. Mazaleyrat, and M. Wakselman. 1991. Acyl-oxybenzyl halides, inhibitors of elastases. Biochim. Biophys. Acta 1076: 401-405 [Medline].
26. Powers, J. C., and W. Harper. 1988. Inhibitors of serine proteinases. In Proteinase Inhibitors. A. J. Barrett and G. Salvesen, editors. Elsevier, Amsterdam. 55-152.
27. Sommerhoff, C. P., J. A. Nadel, C. B. Basbaum, and G. H. Caughey. 1990. Neutrophil elastase and cathepsin G stimulate secretions from cultured bovine airway gland serous cells. J. Clin. Invest. 85: 682-689 .
28. Nakamura, H., K. Yoshimura, N. G. McElvaney, and R. G. Crystal. 1992. Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. J. Clin. Invest. 89: 1478-1484 .
29. Stockley, R. A.. 1994. The role of proteinases in the pathogenesis of chronic bronchitis. Am. J. Respir. Crit. Care Med. 150: S109-S113 .
30. McDaniel, R., A. Thamchaipenet, C. Gustafsson, H. Fu, M. Betlach, M. Betlach, and G. Ashley. 1999. Multiple genetic modifications of the erythromycin polyketide synthase to produce a library of novel "unnatural" natural products. Proc. Natl. Acad. Sci. USA 96:1846-1851. [correction 1999 Proc. Natl. Acad. Sci. USA 97:5011]
This article has been cited by other articles:
![]() |
B. Yates, D. M. Murphy, I. A. Forrest, C. Ward, R. M. Rutherford, A. J. Fisher, J. L. Lordan, J. H. Dark, and P. A. Corris Azithromycin Reverses Airflow Obstruction in Established Bronchiolitis Obliterans Syndrome Am. J. Respir. Crit. Care Med., September 15, 2005; 172(6): 772 - 775. [Abstract] [Full Text] [PDF] |
||||
![]() |
S C Bell, S L Senini, and J G McCormack Macrolides in cystic fibrosis Chronic Respiratory Disease, April 1, 2005; 2(2): 85 - 98. [Abstract] [PDF] |
||||
![]() |
P. J. Barnes Mediators of Chronic Obstructive Pulmonary Disease Pharmacol. Rev., December 1, 2004; 56(4): 515 - 548. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.J. Barnes, S.D. Shapiro, and R.A. Pauwels Chronic obstructive pulmonary disease: molecular and cellularmechanisms Eur. Respir. J., October 1, 2003; 22(4): 672 - 688. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Proc. Am. Thorac. Soc. | Am. J. Respir. Crit. Care Med. |